Bristol Myers Squibb just put Claude AI in the hands of 30,000 employees. Not a pilot programme. Not a research experiment. Full deployment across drug discovery, clinical development, regulatory submissions, manufacturing, and commercial operations. They are also evaluating Claude Code for research and development.
The BMS chief digital officer said it plainly: "Most enterprise AI stops at the chatbot. The real prize is the untapped value still trapped behind decades of data silos." Claude is being connected to thousands of internal data sources, creating a single intelligence layer that can generate clinical study reports from trial data, surface scientific context from decades of research, or trace the root cause of a manufacturing deviation in real time.
McKinsey estimates agentic AI could increase clinical development productivity by 35 to 45% over five years. Eli Lilly is partnering with Nvidia on AI drug discovery too. The pharma industry is not experimenting. It is deploying at scale.
Medical research should be the first place AI is used. For once, it actually is.




















